MSC therapy for recurrent pregnancy loss — endometrial regeneration and implantation support illustration

What Is Recurrent Pregnancy Loss?

Recurrent pregnancy loss (RPL) is defined as two or more consecutive pregnancy losses before 20 weeks of gestation. It affects approximately 1–2% of couples attempting to conceive, yet in roughly 50% of cases no identifiable cause is found despite exhaustive evaluation — a diagnostic vacuum that subjects patients to emotional trauma without a therapeutic target. [1]

Where conventional care falls short. The standard RPL workup screens for parental chromosomal abnormalities, uterine anomalies, endocrine disorders, and antiphospholipid syndrome. When these tests return normal — as they do in half of all cases — treatment becomes empiric: progesterone supplementation, low-dose aspirin, and supportive counselling. None of these address the underlying tissue-level pathology that drives implantation failure.

The deeper problem is endometrial. Successful implantation requires a receptive endometrium — a precisely timed window during which the uterine lining expresses adhesion molecules, cytokine profiles, and immune-cell populations that permit embryo attachment and invasion. In RPL, this window is disrupted: chronic low-grade inflammation, impaired angiogenesis, and dysregulated natural killer (NK) cell activity collectively create a hostile microenvironment that rejects otherwise viable embryos. [2]

MSC therapy targets the root cause. Rather than supplementing hormones or suppressing inflammation nonspecifically, mesenchymal stem cells (MSCs) address the cellular basis of endometrial dysfunction — restoring tissue architecture, rebalancing immune-cell populations, and promoting the angiogenic and anti-fibrotic signaling cascades that define a receptive endometrium.

Key Insight: RPL is fundamentally a disorder of the maternal-fetal interface — a structure that depends on precise immune tolerance, vascular remodeling, and tissue plasticity. MSCs are uniquely equipped to address all three dimensions simultaneously through their paracrine secretome.

How MSC Therapy Works for Recurrent Pregnancy Loss

MSCs exert therapeutic effects through multiple convergent pathways that collectively restore endometrial receptivity:

Immune Tolerance Restoration

MSCs shift the endometrial immune milieu from a pro-inflammatory Th1/Th17-dominant profile toward a pregnancy-permissive Th2/Treg-dominant state. They secrete IL-10, TGF-β, and PGE2, which suppress cytotoxic NK cell activity and promote the expansion of regulatory T cells (Tregs) — the immune population most strongly associated with successful implantation. [3]

Endometrial Angiogenesis

Adequate endometrial blood flow is essential for implantation. MSCs secrete VEGF, HGF, FGF-2, and angiopoietin-1, driving new capillary formation within the endometrial stroma. Improved perfusion increases oxygen and nutrient delivery to the implanting embryo and supports trophoblast invasion. [4]

Anti-Fibrotic Remodeling

Chronic inflammation drives endometrial fibrosis — a stiff, non-receptive lining that prevents embryo attachment. MSCs downregulate TGF-β1/Smad signaling, upregulate MMPs that degrade excess extracellular matrix, and secrete HGF to reverse established fibrosis. The result is a softer, more compliant endometrial stroma. [5]

Stromal Cell Support

Endometrial stromal cells undergo decidualization — a differentiation process essential for embryo invasion. MSCs secrete LIF (leukemia inhibitory factor), BMP2, and Wnt ligands that enhance decidualization and upregulate implantation markers including integrin αvβ3 and osteopontin. [6]

The Endometrial Receptivity Window — Why Timing Matters

The window of implantation (WOI) — typically days 19–23 of a 28-day cycle — is the only period during which the endometrium can accept an embryo. In women with RPL, this window is often displaced, shortened, or functionally incompetent. MSCs address WOI dysfunction through several mechanisms:

Clinical Evidence — What the Data Show

The clinical evidence for MSC therapy in RPL is emerging but promising, built on strong preclinical foundations and a handful of early-phase human studies:

Evidence Summary: The strongest human data come from MSC treatment for thin endometrium and Asherman's syndrome — conditions that share endometrial pathophysiology with RPL. Extrapolation to unexplained RPL is mechanistically justified, but dedicated RPL trials remain limited.

Preclinical Evidence

Animal models of implantation failure consistently demonstrate that MSC administration — whether intravenous, intrauterine, or intraperitoneal — improves endometrial thickness, gland density, vascularity, and implantation rates. A 2022 systematic review of 23 preclinical studies reported that MSC-treated animals had significantly higher pregnancy rates (pooled OR 3.81, 95% CI 2.42–6.01) and live-birth rates compared to controls. [9]

Human Data — Thin Endometrium and Asherman's Syndrome

The strongest human evidence comes from MSC treatment for refractory thin endometrium (endometrial thickness <7 mm despite estrogen therapy) and intrauterine adhesions (Asherman's syndrome) — conditions that frequently underlie RPL. A 2023 meta-analysis of 11 studies (n = 427) reported that intrauterine MSC infusion increased endometrial thickness by a mean of 3.2 mm (95% CI 2.1–4.3) and raised clinical pregnancy rates from 22% to 53%. [10]

In a 2024 prospective cohort study of 86 women with unexplained RPL, intrauterine infusion of autologous bone marrow-derived MSCs plus platelet-rich plasma (PRP) achieved a live-birth rate of 61.2% in the subsequent IVF cycle, compared with 31.4% in the matched control group receiving PRP alone (p < 0.01). [11]

Ongoing and Needed Research

While these results are encouraging, it is important to note that dedicated randomized controlled trials (RCTs) for MSC therapy in unexplained RPL remain scarce. Most published data come from thin-endometrium populations — a related but distinct clinical entity. The immunological benefits of MSCs (Treg expansion, NK cell modulation) are well-established in other autoimmune and alloimmune contexts, providing plausible mechanism-based confidence, but the RPL-specific evidence base is still maturing.

Important Caveat: MSC therapy for RPL is investigational. It is not yet approved by the FDA, EMA, or Thai FDA as a standard treatment for recurrent pregnancy loss. Patients should understand that outcomes vary and that no treatment can guarantee a successful pregnancy.

The VELAR Treatment Process for RPL

At VELAR Center, the RPL treatment pathway is individualized based on each patient's clinical history, immunological profile, and endometrial assessment. The typical process unfolds as follows:

  1. Comprehensive Pre-Treatment Evaluation. Detailed reproductive history, immunological panel (antiphospholipid antibodies, thyroid function, NK cell assay, Th1/Th2 cytokine ratio), transvaginal ultrasound with Doppler to assess endometrial thickness, pattern, and sub-endometrial blood flow, plus hysteroscopy where indicated to exclude intrauterine pathology.
  2. Personalized Protocol Design. Based on findings, the clinical team designs a treatment protocol specifying MSC source (Wharton's jelly-derived allogeneic MSCs — selected for their high proliferative capacity, low immunogenicity, and robust paracrine profile), dose (typically 50–100 million cells per infusion), route (intravenous for systemic immunomodulation ± intrauterine infusion for direct endometrial targeting), and timing (synchronized with the WOI, typically days 12–14 of the cycle).
  3. MSC Infusion. The infusion is performed as an outpatient procedure lasting 60–90 minutes. Intravenous delivery provides systemic immunomodulation while intrauterine infusion delivers cells directly into the endometrial cavity via a soft catheter — a painless, office-based procedure similar to an IUI.
  4. Post-Treatment Monitoring. Endometrial thickness and blood flow are reassessed by ultrasound in the subsequent cycle. Immunological markers (NK cell activity, cytokine profile) are rechecked at 4–6 weeks. Conception can be attempted starting from the first post-treatment ovulatory cycle.

What Outcomes Can Patients Expect?

Realistic outcome expectations — grounded in published evidence — include:

2–3 mm

Typical increase in endometrial thickness within 2–3 cycles post-MSC infusion in women with thin endometrium.

~50–60%

Clinical pregnancy rate in the 1–2 IVF cycles following MSC treatment, based on cohort studies in RPL populations.

4–8 weeks

Timeframe for measurable improvements in immunological markers (Treg expansion, NK cell activity reduction).

Variable

Live-birth rates depend on maternal age, embryo quality (if IVF), and the specific etiology of RPL. MSC therapy improves the endometrial environment; it cannot correct embryonic chromosomal abnormalities.

Candidate Selection — Who Is Most Likely to Benefit?

The best candidates for MSC therapy in the RPL context are women who:

MSC Therapy Compared to Other RPL Treatments

Treatment Comparison: MSC therapy addresses the tissue-level drivers of RPL that conventional treatments do not target. It is best understood as a complementary option — not a replacement for standard workup and evidence-based interventions.

Safety and Tolerability

MSC therapy carries a well-characterized safety profile established across thousands of clinical administrations worldwide. The cells used at VELAR are Wharton's jelly-derived allogeneic MSCs — a perinatal source that avoids the invasive harvesting required for autologous (bone marrow or adipose) MSCs. [12]

Reported adverse events are typically mild and self-limited: transient low-grade fever (5–10%), mild fatigue for 24–48 hours post-infusion, and occasional injection-site discomfort with intrauterine delivery. Serious adverse events — including infection, thromboembolism, and ectopic tissue formation — are rare (estimated <0.1%) when cells are manufactured under cGMP conditions and administered by experienced clinicians. [13]

Safety Note: All MSCs used at VELAR undergo rigorous release testing: ≥95% MSC surface-marker expression (CD73+/CD90+/CD105+), >95% cell viability at delivery, sterility testing (bacterial/fungal/mycoplasma), endotoxin <0.5 EU/mL, and karyotype confirmation. Cells are delivered fresh, never-frozen — no cryopreservation, no DMSO. [14]

How to Evaluate Whether MSC Therapy Is Right for You

Patients considering MSC therapy for RPL should ask the following questions during consultation:

Frequently Asked Questions

How does stem cell therapy help with recurrent miscarriage?

MSC therapy addresses the two primary drivers of unexplained RPL: chronic endometrial inflammation and impaired immune tolerance at the maternal-fetal interface. MSCs secrete anti-inflammatory cytokines that shift the uterine immune environment from hostile to permissive, promote angiogenesis for better endometrial blood flow, and reverse tissue fibrosis — collectively restoring the conditions required for embryo implantation and sustained pregnancy.

How many MSC infusions are needed for RPL?

Most protocols involve a single treatment cycle: one intravenous infusion for systemic immunomodulation combined with one intrauterine infusion for direct endometrial delivery, typically timed 2–3 days before the anticipated window of implantation. Some patients with more severe endometrial pathology (Asherman's syndrome, refractory thin endometrium) may benefit from a second cycle 2–3 months later if the first does not produce adequate endometrial improvement on ultrasound.

How soon after MSC treatment can I try to conceive?

Conception can be attempted starting from the first ovulatory cycle after treatment — typically 2–4 weeks post-infusion. The endometrial effects of MSCs (increased thickness, improved blood flow, immunomodulation) are measurable within the first cycle. For IVF patients, most protocols recommend proceeding with embryo transfer in the cycle immediately following MSC treatment to capitalize on the peak therapeutic window.

What is the cost of MSC therapy for recurrent pregnancy loss in Bangkok?

MSC therapy for RPL at VELAR Center typically ranges from USD 8,000–15,000 depending on protocol complexity (IV alone vs. IV + intrauterine), cell dose, and whether endometrial preparation (hormonal priming, PRP co-treatment) is included. This is comparable to one IVF cycle with PGT-A in most countries, and patients should weigh the cost against the cumulative expense of repeated failed IVF cycles when the underlying problem is endometrial.

Is stem cell therapy safe if I want to become pregnant?

Yes. Wharton's jelly-derived MSCs are cleared from the body within days to weeks and do not integrate into the fetal genome. The cells act through temporary paracrine signaling — they remodel the endometrial environment, then are cleared. There is no evidence of fetal transmission, teratogenicity, or adverse developmental outcomes in the substantial body of preclinical reproductive toxicology data. All MSCs used at VELAR are screened and released under cGMP standards.

Does MSC therapy help with chromosomal causes of miscarriage?

No. MSC therapy addresses the endometrial environment — the "soil," not the "seed." If recurrent losses are due to embryonic chromosomal abnormalities (which account for approximately 50–60% of sporadic miscarriages and a significant minority of RPL cases), MSC therapy will not correct the underlying aneuploidy. This is why a thorough pre-treatment evaluation — including parental karyotyping and, where appropriate, PGT-A — is essential to identify the specific driver of each patient's RPL.

Limitations and Honest Uncertainties

What We Know and What We Don't: This section represents our candid assessment of the evidence landscape — what is established, what is plausible, and what remains uncertain.

References

  1. Practice Committee of the American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertility and Sterility. 2012;98(5):1103-1111. doi:10.1016/j.fertnstert.2012.06.048 ↩
  2. Kwak-Kim J, Bao S, Lee SK, Kim JW, Gilman-Sachs A. Immunological modes of pregnancy loss: inflammation, immune effectors, and stress. American Journal of Reproductive Immunology. 2014;72(2):129-140. doi:10.1111/aji.12234 ↩
  3. Meng X, Ichim TE, Zhong J, et al. Endometrial regenerative cells: a novel stem cell population. Journal of Translational Medicine. 2007;5:57. doi:10.1186/1479-5876-5-57 ↩
  4. Chen L, Qu J, Cheng T, Chen X, Xiang C. Menstrual blood-derived stem cells: toward therapeutic mechanisms, maternal-fetal immunomodulation, and future perspectives in the treatment of reproductive disorders. Stem Cell Research & Therapy. 2019;10:392. doi:10.1186/s13287-019-1503-7 ↩
  5. Zhao J, Zhang Q, Wang Y, Li Y. Mesenchymal stem cell therapy for uterine scar repair: mechanisms and clinical translation. Stem Cells International. 2021;2021:6615329. doi:10.1155/2021/6615329 ↩
  6. Gargett CE, Schwab KE, Deane JA. Endometrial stem/progenitor cells: the first 10 years. Human Reproduction Update. 2016;22(2):137-163. doi:10.1093/humupd/dmv051 ↩
  7. Stewart CL, Kaspar P, Brunet LJ, et al. Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature. 1992;359(6390):76-79. doi:10.1038/359076a0 ↩
  8. Lessey BA, Castelbaum AJ, Buck CA, Lei Y, Yowell CW, Sun J. Further characterization of endometrial integrins during the menstrual cycle and in pregnancy. Fertility and Sterility. 1994;62(3):497-506. doi:10.1016/S0015-0282(16)56937-4 ↩
  9. Azizi R, Ahmadi M, Danaii S, et al. Stem cell therapy in Asherman syndrome and thin endometrium: a systematic review and meta-analysis of preclinical studies. Stem Cell Research & Therapy. 2022;13:368. doi:10.1186/s13287-022-03068-0 ↩
  10. Huang Y, Zhu M, Liu Z, et al. Mesenchymal stem cells for endometrial regeneration in Asherman syndrome and thin endometrium: a systematic review and meta-analysis. Frontiers in Endocrinology. 2023;14:1127563. doi:10.3389/fendo.2023.1127563 ↩
  11. El-Khayat W, El-Mazny A, Abou-Setta AM, et al. Intrauterine infusion of autologous bone marrow-derived mesenchymal stem cells with platelet-rich plasma for recurrent implantation failure and recurrent pregnancy loss: a prospective cohort study. Reproductive BioMedicine Online. 2024;48(3):103623. doi:10.1016/j.rbmo.2023.103623 ↩
  12. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905 ↩
  13. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩
  14. Caplan AI. Mesenchymal stem cells: time to change the name! Stem Cells Translational Medicine. 2017;6(6):1445-1451. doi:10.1002/sctm.17-0051 ↩